Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## CHINA HEALTH GROUP INC.

# 中國醫療集團有限公司

(Carrying on business in Hong Kong as "萬全醫療集團") (Formerly known as "Venturepharm Laboratories Limited") (Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8225)

- (1) APPOINT CHIEF MEDICAL OFFICER (2) APPOINT FINANCIAL DIRECTOR
  - (3) APPOINT COMPANY SECRETARY

## The Board announces that with effect from 15 April 2016:

- (1) Mr. Albert Qin has been appointed as the Chief Medical Officer of the Group;
- (2) Mr. Liang Li has been appointed as the Financial Director of the Group; and
- (3) Ms. Jing Xu has been appointed as Company Secretary of the Company.

The board (the "Board") of directors (the "Directors") of China Health
Group Inc.(the "Company"), together with its subsidiaries (the "Group")
hereby announces the below appointments with effect from 15 April 2016:

#### APPOINT CHIEF MEDICAL OFFICER

Albert Qin has been appointed as the Chief Medical Officer of the Group. Set out below is the biography of Dr. Qin:

Mr. Qin holds Ph.D. degree in Molecular Pharmacology and Biochemistry from Harvard Medical School. Dr. Qin served as Chief Scientific Officer and Corporate Officer, SymBio Pharmaceuticals in Tokyo, Japan from 2011 to 2015, concurrently holding Medical Director of R&D position (2010 to 2015). From2006 to 2010, Dr. Qin served as Medical Director and Head of Clinical Development, ImmunoGen Inc., US. From 2004 to 2006, Dr. Qin served as Associate Director, Pfizer Global Clinical Development, US. From 2002 to 2004, Dr. Qin served as Senior Research Scientist II, Bayer Pharmaceuticals, US. From 1994 to 2002, Dr. Qin served as Scientist to Senior Scientist, Biogen Inc., US. Made multiple important discoveries in interferon research, immunology, and gene therapy. Dr. Qin joined the Group on 14 March 2016.

### APPOINT FINANCIAL DIRECTOR

Mr. Liang Li has been appointed as the Financial Director of the Group. Set out below is the biography of Mr. Li:

Mr. Li holds Master of Science Degree in International Accounting and Finance from London School of Economics, U.K. and Bachelor of Economics Degree in International Finance from Shanghai University of Finance and Economics, China. Mr. Li is a member of the Association of Chartered Certified Accountants as well as a member of the Chinese Institute of Certified Public Accountants.

Mr. Li has over sixteen years of experience in finance management and auditing. From June 2008 to February 2016, Mr. Li served as Financial Controller in Jubilant Life Sciences (Shanghai) Co., Ltd, which is the subsidiary of Jubilant Life Science Inc. From January 2003 to May 2008, Mr. Li served as Financial Controller in Shanghai Labway Scientific Development

Co., Ltd. Before this Mr. Li served in Deloitte Touche Tomatsu (Shanghai)

CPA Firm and several multinational companies in the auditing and financial management areas. Mr. Li joined the Group on 1 March 2016.

#### APPOINT COMPANY SECRETARY

Ms. Jing Xu has been appointed as Company Secretary of the Company. Set out below is the biography of Ms. Xu:

Ms. Xu Jing holds a Bachelor of Management from Zhongnan University of Economics and Law, major in Accounting (Special orientation of CPA). She is a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Certified Public Accountants ,She also is the member of the Chinese Institute of Certified Public Accountants.

Ms. Xu has over thirteen years of experience in finance management, tax planning and management, investing and financing management, internal control and company secretary services. From July 2002 to May 2007, Ms. Xu served as an Accountant in Yulong Computer Telecommunication Scientific (Shenzhen) Co., Ltd which is the fully owned subsidiary of Coolpad Group Limited (HKEX listed company, stock code: 2369), being one of the core IPO team members; From June 2007 to March 2012, Ms. Xu served as Financial Controller and Qualified Accountant in Shenzhen Neptunus Interlong Bio-technology Company Ltd (HKGEM listed company, stock code: 8329); From February 2012 to April 2015, Ms. Xu served as Financial Director in a non-public company in Shenzhen. Ms. Xu joined the Group on 10 December 2015.

By Order of the Board

China Health Group Inc. William Xia Guo

Chairman

Beijing RPC, 18 April 2016

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and

 $Dr.\ Maria\ Xue\ Mei\ Song;\ one\ non-executive\ director,\ being\ Dr.\ Nathan\ Xin\ Zhang;\ and\ three\ independent\ non-executive\ directors,$ 

being Dr. Shou Yuan Wu, Mr. Mark Gavin Lotte and Dr. Bin Hui Ni.

This announcement, for which the directors of the Company (the "Directors") collectively and individually accept

responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the

Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the

Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and

belief: (1) the information contained in this announcement is accurate and complete in all material respect and not

misleading; (2) there are no other matters the omission of which would make any statement in all material

respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due

and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on

the "Latest Company Announcements" page for at least 7days from the date of its posting and on

the Company's website at www. chgi. net

4